CN103637348A - 一种预防动脉硬化的葛根粉冲剂及制作方法 - Google Patents
一种预防动脉硬化的葛根粉冲剂及制作方法 Download PDFInfo
- Publication number
- CN103637348A CN103637348A CN201310644771.XA CN201310644771A CN103637348A CN 103637348 A CN103637348 A CN 103637348A CN 201310644771 A CN201310644771 A CN 201310644771A CN 103637348 A CN103637348 A CN 103637348A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- kudzu
- blood
- vine root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 71
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 206010003210 Arteriosclerosis Diseases 0.000 title abstract description 6
- 241000219780 Pueraria Species 0.000 title abstract 5
- 239000008187 granular material Substances 0.000 title abstract 4
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 23
- 244000000626 Daucus carota Species 0.000 claims abstract description 22
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 22
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 21
- 240000004922 Vigna radiata Species 0.000 claims abstract description 21
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 21
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 21
- 244000068988 Glycine max Species 0.000 claims abstract description 19
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 19
- 240000008042 Zea mays Species 0.000 claims abstract description 17
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 17
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 17
- 235000005822 corn Nutrition 0.000 claims abstract description 17
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 15
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 15
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 14
- 244000269722 Thea sinensis Species 0.000 claims abstract description 7
- 235000021016 apples Nutrition 0.000 claims abstract description 6
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract 5
- 244000046146 Pueraria lobata Species 0.000 claims description 43
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 43
- 241000220225 Malus Species 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 14
- 235000005412 red sage Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000005862 Whey Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 7
- 235000009569 green tea Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 235000002020 sage Nutrition 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000004575 stone Substances 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 48
- 210000004369 blood Anatomy 0.000 abstract description 33
- 239000008280 blood Substances 0.000 abstract description 33
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 22
- 235000018102 proteins Nutrition 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 235000012000 cholesterol Nutrition 0.000 abstract description 11
- 229910052742 iron Inorganic materials 0.000 abstract description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract description 10
- ROFJUMITFMRBRF-UHFFFAOYSA-N fagopyrin Chemical compound CC1=CC(O)=C(C(C2=C3O)=O)C4=C1C1=C(C)C=C(O)C(C(C=5C(O)=C(C6NCCCC6)C(O)=C6C7=5)=O)=C1C7=C4C2=C6C(O)=C3C1CCCCN1 ROFJUMITFMRBRF-UHFFFAOYSA-N 0.000 abstract description 10
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 abstract description 10
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000036772 blood pressure Effects 0.000 abstract description 9
- 239000011575 calcium Substances 0.000 abstract description 9
- 229910052791 calcium Inorganic materials 0.000 abstract description 9
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract description 9
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 9
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract description 9
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract description 9
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 9
- 235000005493 rutin Nutrition 0.000 abstract description 9
- 229960004555 rutoside Drugs 0.000 abstract description 9
- 210000004556 brain Anatomy 0.000 abstract description 8
- 235000013734 beta-carotene Nutrition 0.000 abstract description 7
- 239000011648 beta-carotene Substances 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000036770 blood supply Effects 0.000 abstract description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 abstract description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract description 5
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 abstract description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 abstract description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 abstract description 5
- 229960002747 betacarotene Drugs 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000002490 cerebral effect Effects 0.000 abstract description 5
- 235000008777 kaempferol Nutrition 0.000 abstract description 5
- 239000000787 lecithin Substances 0.000 abstract description 5
- 229940067606 lecithin Drugs 0.000 abstract description 5
- 235000010445 lecithin Nutrition 0.000 abstract description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract description 5
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 abstract description 5
- 239000011574 phosphorus Substances 0.000 abstract description 5
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 5
- 235000019192 riboflavin Nutrition 0.000 abstract description 5
- 239000002151 riboflavin Substances 0.000 abstract description 5
- 229960002477 riboflavin Drugs 0.000 abstract description 5
- 239000011701 zinc Substances 0.000 abstract description 5
- 229910052725 zinc Inorganic materials 0.000 abstract description 5
- 230000004087 circulation Effects 0.000 abstract description 3
- 150000002576 ketones Chemical class 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 244000070406 Malus silvestris Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- 235000021119 whey protein Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 241000219051 Fagopyrum Species 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- 208000034189 Sclerosis Diseases 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 8
- 150000002215 flavonoids Chemical class 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 7
- -1 268 milligrams Chemical compound 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001077 hypotensive effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000001142 anti-diarrhea Effects 0.000 description 4
- 230000008344 brain blood flow Effects 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 239000000496 cardiotonic agent Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 235000008935 nutritious Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010002368 Anger Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 2
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000003995 melancholia Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 150000002814 niacins Chemical class 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229940067626 phosphatidylinositols Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述原料配方、重量比为:葛根粉600-1000份、大豆、荞麦各300-500份、绿豆、胡萝卜、苹果各200-300份、葵花籽100-160份、茶叶、丹参、玉米须、乳清蛋白粉各60-100份。本发明所述的预防动脉硬化的葛根粉冲剂,营养丰富、搭配合理,主要包括酮类、蛋白质、不饱和脂肪酸、卵磷脂、β-胡萝卜素、核黄素、苦味素、山奈酚、荞麦碱、芸香苷以及铁、锰、锌、钙、磷等,能扩张脑血管,抑制凝血块的形成,增加脑及冠状动脉血流量,改善脑血液循环,增加微血管的韧性和弹性,抑制动脉壁硬化的防治,确保供血良好。同时能降血脂、调节血压、胆固醇。
Description
技术领域
本发明涉及食品加工领域,具体涉及一种预防动脉硬化的葛根粉冲剂及制作方法。
背景技术
如今,国人的饮食日渐西化,饮食中若含有大量的胆固醇和动物性脂肪时,会使得血液中的脂肪浓度增加、胆固醇浓度增加,同时会逐渐的沉积在动脉血管的管壁里,最后造成血管硬化阻塞,进而造成冠状动脉疾病,心肌缺氧、心肌梗塞、高血压,以及脑中风等血管病变。
动脉硬化的表现主要决定于血管病变及受累器官的缺血程度,对于早期的动脉硬化患者,大多数患者几乎都没有任何临床症状,都处在隐匿状态下潜伏发展。对于中期的动脉硬化患者,大多数患者都或多或少有心悸、胸痛、胸闷、头痛、头晕、四肢凉麻、四肢酸懒、跛行、视力降低、记忆力下降、失眠多梦等临床症状,不同的患者会有不同的症状。动脉硬化是导致心脑血管疾病的重要因素,因此防治动脉硬化意义重大。
发明内容
本发明就是针对上述现状,而提供一种预防动脉硬化的葛根粉冲剂及制作方法。
一种预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比及制作方法如下。
步骤1:挑选、称取优质的原料:葛根粉600-1000份、大豆300-500份、荞麦300-500份、绿豆200-300份、胡萝卜200-300份、苹果200-300份、葵花籽100-160份、茶叶60-100份、丹参60-100份、玉米须60-100份、乳清蛋白粉60-100份。
步骤2:将上述大豆、荞麦洗净、沥干、炒熟后,用粉碎机研磨加工成粉;
将上述绿豆晒干后,用粉碎机研磨加工成粉;
选用新鲜苹果去皮、去核、晒干后用粉碎机打磨加工成粉,制成苹果粉;
将上述新鲜胡萝卜洗净、蒸熟、打碎、烘干、粉碎后,得胡萝卜粉;
将上述葵花籽炒熟后,用粉碎机研磨加工成粉;
将上述绿茶炒青,再用粉碎机或石磨加工研磨,得绿茶粉;
将上述丹参、玉米须晒干或烘干后,研磨加工成粉。
步骤3:将上述加工好的粉剂及葛根粉过150-220目筛,将筛上物进一步研磨后,再次过筛。
步骤4:将过筛后的粉剂与乳清蛋白粉充分搅拌10-15分钟,直至均匀。
步骤5:将步骤4所得混合粉剂进行杀菌、喷雾干燥处理,杀菌温度90-95℃、时间为1-2分钟。
步骤6:经检验合格后,进行分袋包装,每小袋重量为20-30克,每15-20小袋合并包装成一大袋。
本发明所述的葛根粉中主要原料的营养成分及功能如下。
上述葛根粉含黄酮类物质,能扩张脑血管,改善脑血液循环,确保脑供血良好。葛根具有降血脂、调节血压,增加脑及冠状动脉血流量,对垂体后叶素引起的心脏病缺血反应有保护作用,对冠心病心绞痛以及高血压导致的头痛均有疗效。
上述大豆含有一种皂甙的物质,可以降低血液中胆固醇的含量。大豆还含有丰富的黄酮类、食用纤维、不饱和脂肪酸、卵磷脂、磷脂酰胆碱、钙等,具有良好的降血脂作用。另外,大豆中含有大量的铁质,而铁质是承载能量的主要介质(血红蛋白可以承载人体所需的养份),所以,当人体缺铁时就会导致人体贫血,使人头晕、乏力。
上述荞麦含有一些特殊营养成分,如:苦味素、荞麦碱、芸香苷(芦丁)、黄酮类等成分。其中尤其是云香碱对降压作用明显,黄酮类具有增强心肌泵功能,增强冠状动脉的供血量预防冠心病和心律紊乱。
荞麦中还含有丰富的赖氨酸成分,铁、锰、锌等微量元素,比一般谷物丰富,荞麦具有降低血糖的功效,它含有的烟酸成分能促进机体的新陈代谢,增强解毒能力,具有扩张小血管和降低血液胆固醇的作用。荞麦中含有丰富的镁,能促进人体纤维蛋白溶解,使血管扩张,抑制凝血块的形成,具有抗栓塞的作用,也有利于降低血清胆固醇。
上述绿豆性凉味甘,入脾、胃经,养脾胃、防动脉硬化,具有消暑止渴、清热解毒、利尿润肤的功能,能祛火、治暑热烦渴、水肿、泻利、丹毒、痈肿、解热毒、解体内毒素,夏天吃绿豆能祛火也能解毒。每百克绿豆含蛋白质22.1克、脂肪0.8克、碳水化物59克、钙49毫克、磷268毫克、铁3.2毫克、胡萝卜素0.22毫克、硫胺素0.53毫克、核黄素0.12毫克、尼克酸1.8毫克。其中,蛋白质主为球蛋白类,其组成中蛋氨酸、色氨酸和酪氨酸较少。绿豆的磷脂成分中有磷脂酰胆碱、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰甘油、磷脂酰丝氨酸、磷脂酸。
上述胡萝卜含有丰富的β-胡萝卜素、槲皮素、山奈酚、食用纤维等,具有降血脂、抗氧化、预防脂质过氧化作用。胡萝卜可增加冠状动脉血流量,降低血脂,促进肾上腺素合成,因此而具有降血压、强心等效能。
另外,胡萝卜中还含有大量备受医学专家重视的维生素A原,国内外研究成果均指出,它不仅是可养眼蔬菜,还可提高人体抗感染能力,又是有效地防癌蔬菜。
上述苹果含有优质果胶,它会和胆固醇结合,帮助人体将胆固醇排出体外,达到降胆固醇的目的,而苹果里的果胶也会和胆囊中的胆固醇结合排出,可以稀释胆汁,有预防胆结石的效果。苹果中含有丰富的钾,可排出体内多余的钠盐,维持正常的血压,具有生津止渴、益脾止泻、和胃降逆的功效,用于中气不足、腹泻、便秘等。苹果中富含的维生素C,是心血管的保护神,心脏病患者的健康元素,苹果可以降肝火、胃火、大肠火,对于身体排毒、排泄大有好处。医学认为苹果具有降低血脂、润肺除烦、健脾益胃、养心益气等功效。
上述葵花籽具有清肝泻火、养心安神作用,调节人体新陈代谢、保持血压稳定及降低血中胆固醇,可防止不饱和脂肪酸在体内过度氧化,并活化毛细血管、促进血液循环,达到抗氧化、防衰老的效果。葵花子还能增强记忆力,预防癌症、忧郁症、失眠症和心血管等疾病的发生。
葵花子营养丰富,富含铁,能改善脱发、悦色美容。每100克葵花子中含有蛋白质23.1克、脂肪51.1克、糖9.6克、热量2169.4千焦、钙42毫克、磷334毫克、铁4.0毫克。葵花子含脂肪油可达50%左右,并含多量亚油酸(达70%),尚有磷脂、一谷甾醇等甾醇。亚油酸部分能抑制实验性血栓的形成,对预防高脂血症及血栓形成亦是有益的。
上述茶叶经研究证明,其中的茶多酚能降低血液中胆固醇和三酸甘油脂的含量,增加微血管的韧性和弹性,降低血脂,从而防止高血压及心脑血管等疾病。另外茶叶有提神、强心、利尿、消腻和降脂之功。茶叶中的茶多酚不仅能去脂肪而且还具有明显地抑制血浆和肝脏中胆固醇含量的上升,抑制动脉壁硬化的防治。研究表明,茶色素(儿茶素氧化而成)具有显著的抗血凝、促进纤维蛋白溶解、防止血小板的粘附聚焦及抑制动脉平滑肌细胞增生等作用。
上述丹参中的丹参素和原儿茶醛含量较高、活性较强,是丹参治疗冠心病的主要有效成分之一。研究证明丹参是一种钙拮抗剂。钙拮抗剂几乎影响所有AS发病机理的重要环节,可能通过改变细胞内外代谢或生理过程,最终影响AS的形成。丹参还是一种抗氧化剂:实验证明抗氧化剂能阻止LDL的过氧化,并抑制模型家兔AS病变的发展。
上述玉米须具有很好的降血压之功效,而且也具有止泻、止血和养胃之疗效。玉米须治疗因肾炎引起的浮肿和高血压的疗效尤为明显,能利尿消肿和降脂,适合高血脂者,可防止动脉粥样硬化。
上述乳清蛋白粉被称为蛋白之王,是从牛奶中提取的一种蛋白质,具有营养价值高、易消化吸收、含有多种活性成分等特点,是公认的人体优质蛋白质补充剂之一,主要成分有α-乳白蛋白、β-乳球蛋白、免疫球蛋白、乳铁蛋白,具有免疫活性、抗氧化、消灭或抑制细菌,促进正常细胞生长、提高免疫力的作用。
本发明所述的预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比为:葛根粉700-900份、大豆350-450份、荞麦350-450份、绿豆220-280份、胡萝卜220-280份、苹果220-280份、葵花籽120-140份、茶叶70-90份、丹参70-90份、玉米须70-90份、乳清蛋白粉70-90份。
本发明所述的预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比为:葛根粉800份、大豆400份、荞麦400份、绿豆250份、胡萝卜250份、苹果250份、葵花籽130份、茶叶80份、丹参80份、玉米须80份、乳清蛋白粉80份。
由上可知,本发明与现有葛根粉相比,有如下的优点。
本发明所述的预防动脉硬化的葛根粉冲剂,营养丰富、搭配合理、冲泡即食。其成分主要包括酮类、食用纤维、蛋白质、不饱和脂肪酸、卵磷脂、磷脂酰胆碱、β-胡萝卜素、槲皮素、硫胺素、核黄素、苦味素、山奈酚、荞麦碱、芸香苷(芦丁)以及铁、锰、锌、钙、磷等,能扩张脑血管,抑制凝血块的形成,增加脑及冠状动脉血流量,改善脑血液循环,增加微血管的韧性和弹性,抑制动脉壁硬化的防治,确保供血良好。同时能降血脂、调节血压、帮助人体将胆固醇排出体外,降低血液中胆固醇的含量,促进正常细胞生长、提高免疫力的作用。
具体实施方式
为了彻底了解本发明,将在下列的描述中提出详细的配方组成。显然,本发明的施行并不限定于本领域的技术人员所熟习的特殊细节。本发明的较佳实施例详细描述如下,然而除了这些详细描述外,本发明还可以具有其他实施方式。
实施例1:一种预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比及制作方法如下。
步骤1:挑选、称取优质的原料:葛根粉800份、大豆400份、荞麦400份、绿豆250份、胡萝卜250份、苹果250份、葵花籽130份、茶叶80份、丹参80份、玉米须80份、乳清蛋白粉80份。
步骤2:将上述大豆、荞麦洗净、沥干、炒熟后,用粉碎机研磨加工成粉;
将上述绿豆晒干后,用粉碎机研磨加工成粉;
选用新鲜苹果去皮、去核、晒干后用粉碎机打磨加工成粉,制成苹果粉;
将上述新鲜胡萝卜洗净、蒸熟、打碎、烘干、粉碎后,得胡萝卜粉;
将上述葵花籽炒熟后,用粉碎机研磨加工成粉;
将上述绿茶炒青,再用粉碎机或石磨加工研磨,得绿茶粉;
将上述丹参、玉米须晒干或烘干后,研磨加工成粉。
步骤3:将上述加工好的粉剂及葛根粉过200目筛,将筛上物进一步研磨后,再次过筛。
步骤4:将过筛后的粉剂与乳清蛋白粉充分搅拌12分钟,直至均匀。
步骤5:将步骤4所得混合粉剂进行杀菌、喷雾干燥处理,杀菌温度95℃、时间为1分钟。
步骤6:经检验合格后,进行分袋包装,每小袋重量为25克,每20小袋合并包装成一大袋。
本发明所述的预防动脉硬化的葛根粉冲剂,营养丰富、搭配合理、冲泡即食。其成分主要包括酮类、食用纤维、蛋白质、不饱和脂肪酸、卵磷脂、磷脂酰胆碱、β-胡萝卜素、槲皮素、硫胺素、核黄素、苦味素、山奈酚、荞麦碱、芸香苷(芦丁)以及铁、锰、锌、钙、磷等,能扩张脑血管,抑制凝血块的形成,增加脑及冠状动脉血流量,改善脑血液循环,增加微血管的韧性和弹性,抑制动脉壁硬化的防治,确保供血良好。同时能降血脂、调节血压、帮助人体将胆固醇排出体外,降低血液中胆固醇的含量,促进正常细胞生长、提高免疫力的作用。
本发明所述的葛根粉中主要原料的营养成分及功能如下。
上述葛根粉含黄酮类物质,能扩张脑血管,改善脑血液循环,确保脑供血良好。葛根具有降血脂、调节血压,增加脑及冠状动脉血流量,对垂体后叶素引起的心脏病缺血反应有保护作用,对冠心病心绞痛以及高血压导致的头痛均有疗效。
上述大豆含有一种皂甙的物质,可以降低血液中胆固醇的含量。大豆还含有丰富的黄酮类、食用纤维、不饱和脂肪酸、卵磷脂、磷脂酰胆碱、钙等,具有良好的降血脂作用。另外,大豆中含有大量的铁质,而铁质是承载能量的主要介质(血红蛋白可以承载人体所需的养份),所以,当人体缺铁时就会导致人体贫血,使人头晕、乏力。
上述荞麦含有一些特殊营养成分,如:苦味素、荞麦碱、芸香苷(芦丁)、黄酮类等成分。其中尤其是云香碱对降压作用明显,黄酮类具有增强心肌泵功能,增强冠状动脉的供血量预防冠心病和心律紊乱。
荞麦中还含有丰富的赖氨酸成分,铁、锰、锌等微量元素,比一般谷物丰富,荞麦具有降低血糖的功效,它含有的烟酸成分能促进机体的新陈代谢,增强解毒能力,具有扩张小血管和降低血液胆固醇的作用。荞麦中含有丰富的镁,能促进人体纤维蛋白溶解,使血管扩张,抑制凝血块的形成,具有抗栓塞的作用,也有利于降低血清胆固醇。
上述绿豆性凉味甘,入脾、胃经,养脾胃、防动脉硬化,具有消暑止渴、清热解毒、利尿润肤的功能,能祛火、治暑热烦渴、水肿、泻利、丹毒、痈肿、解热毒、解体内毒素,夏天吃绿豆能祛火也能解毒。每百克绿豆含蛋白质22.1克、脂肪0.8克、碳水化物59克、钙49毫克、磷268毫克、铁3.2毫克、胡萝卜素0.22毫克、硫胺素0.53毫克、核黄素0.12毫克、尼克酸1.8毫克。其中,蛋白质主为球蛋白类,其组成中蛋氨酸、色氨酸和酪氨酸较少。绿豆的磷脂成分中有磷脂酰胆碱、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰甘油、磷脂酰丝氨酸、磷脂酸。
上述胡萝卜含有丰富的β-胡萝卜素、槲皮素、山奈酚、食用纤维等,具有降血脂、抗氧化、预防脂质过氧化作用。胡萝卜可增加冠状动脉血流量,降低血脂,促进肾上腺素合成,因此而具有降血压、强心等效能。
另外,胡萝卜中还含有大量备受医学专家重视的维生素A原,国内外研究成果均指出,它不仅是可养眼蔬菜,还可提高人体抗感染能力,又是有效地防癌蔬菜。
上述苹果含有优质果胶,它会和胆固醇结合,帮助人体将胆固醇排出体外,达到降胆固醇的目的,而苹果里的果胶也会和胆囊中的胆固醇结合排出,可以稀释胆汁,有预防胆结石的效果。苹果中含有丰富的钾,可排出体内多余的钠盐,维持正常的血压,具有生津止渴、益脾止泻、和胃降逆的功效,用于中气不足、腹泻、便秘等。苹果中富含的维生素C,是心血管的保护神,心脏病患者的健康元素,苹果可以降肝火、胃火、大肠火,对于身体排毒、排泄大有好处。医学认为苹果具有降低血脂、润肺除烦、健脾益胃、养心益气等功效。
上述葵花籽具有清肝泻火、养心安神作用,调节人体新陈代谢、保持血压稳定及降低血中胆固醇,可防止不饱和脂肪酸在体内过度氧化,并活化毛细血管、促进血液循环,达到抗氧化、防衰老的效果。葵花子还能增强记忆力,预防癌症、忧郁症、失眠症和心血管等疾病的发生。
葵花子营养丰富,富含铁,能改善脱发、悦色美容。每100克葵花子中含有蛋白质23.1克、脂肪51.1克、糖9.6克、热量2169.4千焦、钙42毫克、磷334毫克、铁4.0毫克。葵花子含脂肪油可达50%左右,并含多量亚油酸(达70%),尚有磷脂、一谷甾醇等甾醇。亚油酸部分能抑制实验性血栓的形成,对预防高脂血症及血栓形成亦是有益的。
上述茶叶经研究证明,其中的茶多酚能降低血液中胆固醇和三酸甘油脂的含量,增加微血管的韧性和弹性,降低血脂,从而防止高血压及心脑血管等疾病。另外茶叶有提神、强心、利尿、消腻和降脂之功。茶叶中的茶多酚不仅能去脂肪而且还具有明显地抑制血浆和肝脏中胆固醇含量的上升,抑制动脉壁硬化的防治。研究表明,茶色素(儿茶素氧化而成)具有显著的抗血凝、促进纤维蛋白溶解、防止血小板的粘附聚焦及抑制动脉平滑肌细胞增生等作用。
上述丹参中的丹参素和原儿茶醛含量较高、活性较强,是丹参治疗冠心病的主要有效成分之一。研究证明丹参是一种钙拮抗剂。钙拮抗剂几乎影响所有AS发病机理的重要环节,可能通过改变细胞内外代谢或生理过程,最终影响AS的形成。丹参还是一种抗氧化剂:实验证明抗氧化剂能阻止LDL的过氧化,并抑制模型家兔AS病变的发展。
上述玉米须具有很好的降血压之功效,而且也具有止泻、止血和养胃之疗效。玉米须治疗因肾炎引起的浮肿和高血压的疗效尤为明显,能利尿消肿和降脂,适合高血脂者,可防止动脉粥样硬化。
上述乳清蛋白粉被称为蛋白之王,是从牛奶中提取的一种蛋白质,具有营养价值高、易消化吸收、含有多种活性成分等特点,是公认的人体优质蛋白质补充剂之一,主要成分有α-乳白蛋白、β-乳球蛋白、免疫球蛋白、乳铁蛋白,具有免疫活性、抗氧化、消灭或抑制细菌,促进正常细胞生长、提高免疫力的作用。
实施例2:本发明所述的预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比为:葛根粉700份、大豆350份、荞麦300份、绿豆280份、胡萝卜280份、苹果260份、葵花籽140份、茶叶90份、丹参85份、玉米须70份、乳清蛋白粉90份,其制作方法同实施例1。
实施例3:本发明所述的预防动脉硬化的葛根粉冲剂,其特征在于:所述葛根粉的原料配方、重量比为:葛根粉9000份、大豆450份、荞麦400份、绿豆280份、胡萝卜280份、苹果300份、葵花籽160份、茶叶100份、丹参80份、玉米须90份、乳清蛋白粉100份,其制作方法同实施例1。
虽然以上描述了本发明中预防动脉硬化的葛根粉冲剂的具体实施方式,但是熟悉本技术领域的技术人员应当理解,我们所描述的具体的实施例只是说明性的,而不是用于对本发明的范围的限定,熟悉本领域的技术人员在依照本发明的精神所作的等效的修饰以及变化,都应当涵盖在本发明的权利要求所保护的范围内。
Claims (3)
1.一种预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比及制作方法如下:
步骤1:挑选、称取优质的原料:葛根粉600-1000份、大豆300-500份、荞麦300-500份、绿豆200-300份、胡萝卜200-300份、苹果200-300份、葵花籽100-160份、茶叶60-100份、丹参60-100份、玉米须60-100份、乳清蛋白粉60-100份;
步骤2:将上述大豆、荞麦洗净、沥干、炒熟后,用粉碎机研磨加工成粉;
将上述绿豆晒干后,用粉碎机研磨加工成粉;
选用新鲜苹果去皮、去核、晒干后用粉碎机打磨加工成粉,制成苹果粉;
将上述新鲜胡萝卜洗净、蒸熟、打碎、烘干、粉碎后,得胡萝卜粉;
将上述葵花籽炒熟后,用粉碎机研磨加工成粉;
将上述绿茶炒青,再用粉碎机或石磨加工研磨,得绿茶粉;
将上述丹参、玉米须晒干或烘干后,研磨加工成粉;
步骤3:将上述加工好的粉剂及葛根粉过150-220目筛,将筛上物进一步研磨后,再次过筛;
步骤4:将过筛后的粉剂与乳清蛋白粉充分搅拌10-15分钟,直至均匀;
步骤5:将步骤4所得混合粉剂进行杀菌、喷雾干燥处理,杀菌温度90-95℃、时间为1-2分钟;
步骤6:经检验合格后,进行分袋包装,每小袋重量为20-30克,每15-20小袋合并包装成一大袋。
2.根据权利要求1所述的预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比为:葛根粉700-900份、大豆350-450份、荞麦350-450份、绿豆220-280份、胡萝卜220-280份、苹果220-280份、葵花籽120-140份、茶叶70-90份、丹参70-90份、玉米须70-90份、乳清蛋白粉70-90份。
3.根据权利要求1所述的预防动脉硬化的葛根粉冲剂及制作方法,其特征在于:所述葛根粉的原料配方、重量比为:葛根粉800份、大豆400份、荞麦400份、绿豆250份、胡萝卜250份、苹果250份、葵花籽130份、茶叶80份、丹参80份、玉米须80份、乳清蛋白粉80份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310644771.XA CN103637348A (zh) | 2013-12-05 | 2013-12-05 | 一种预防动脉硬化的葛根粉冲剂及制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310644771.XA CN103637348A (zh) | 2013-12-05 | 2013-12-05 | 一种预防动脉硬化的葛根粉冲剂及制作方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103637348A true CN103637348A (zh) | 2014-03-19 |
Family
ID=50242755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310644771.XA Pending CN103637348A (zh) | 2013-12-05 | 2013-12-05 | 一种预防动脉硬化的葛根粉冲剂及制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103637348A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104041641A (zh) * | 2014-07-03 | 2014-09-17 | 句容茅宝葛业有限公司 | 一种葛根干姜茶及其制备方法 |
CN104431726A (zh) * | 2014-12-11 | 2015-03-25 | 山东秦老太食品有限公司 | 一种速溶食品甜沫的制备方法 |
CN110692973A (zh) * | 2019-10-29 | 2020-01-17 | 湖北绿珍生态农业开发有限公司 | 一种预防心脑血管疾病的葛根粉工艺的研发 |
CN114868891A (zh) * | 2022-03-26 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用心脑血管患者营养素配方 |
-
2013
- 2013-12-05 CN CN201310644771.XA patent/CN103637348A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104041641A (zh) * | 2014-07-03 | 2014-09-17 | 句容茅宝葛业有限公司 | 一种葛根干姜茶及其制备方法 |
CN104431726A (zh) * | 2014-12-11 | 2015-03-25 | 山东秦老太食品有限公司 | 一种速溶食品甜沫的制备方法 |
CN110692973A (zh) * | 2019-10-29 | 2020-01-17 | 湖北绿珍生态农业开发有限公司 | 一种预防心脑血管疾病的葛根粉工艺的研发 |
CN114868891A (zh) * | 2022-03-26 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用心脑血管患者营养素配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101181058B (zh) | 增强人体五脏机能的五行果蔬营养制剂及其制备方法 | |
CN107173694A (zh) | 一种营养全面平衡的全素食代餐粉配方 | |
CN104054769B (zh) | 一种治疗心血管疾病的功能面包及其制作方法 | |
CN101642247B (zh) | 一种降脂降压方便食品及其加工方法 | |
CN104351795A (zh) | 一种辅助降血压代餐粉及其制备方法 | |
KR20120076857A (ko) | 오디를 이용한 선식 및 그 제조방법 | |
CN105455047A (zh) | 一种保健鲤鱼丸及其制备方法 | |
CN107114663A (zh) | 一种果蔬养胃米粉及其制备方法 | |
WO2011060585A1 (zh) | 含有五色果蔬精华的咀嚼片剂及其制备方法 | |
CN105341668A (zh) | 一种藜麦养生粥 | |
CN104351790A (zh) | 保健食品 | |
CN103637348A (zh) | 一种预防动脉硬化的葛根粉冲剂及制作方法 | |
Arumugam et al. | Fruits and vegetables as Superfoods: Scope and demand | |
CN108887564A (zh) | 一种硒蛋白杂粮粉配方及其制备方法 | |
CN105212219A (zh) | 一种含桑葚的复合营养粉及其制备方法 | |
CN104585398A (zh) | 一种紫薯速溶奶茶粉及该奶茶粉中紫薯粉的制备方法 | |
CN106723075A (zh) | 一种双参沙棘g蛋白肉苁蓉锌硒制剂及其制备方法 | |
CN102100345A (zh) | 一种以紫薯为主要原料的保健休闲食品 | |
CN105029176A (zh) | 一种山楂复合保健营养米粉及其加工方法 | |
CN105768058A (zh) | 一种鸡枞菌香菇菜肴的全素制作方法及该方法得到的菜肴 | |
CN108887683A (zh) | 一种药食养生的米饭添加剂及其制备工艺和药食养生米饭 | |
KR20070037540A (ko) | 인삼 오색두부 제조법 | |
CN103636791A (zh) | 不上火的健康奶粉 | |
CN109007552A (zh) | 一种五彩营养保健米粉及加工方法 | |
KR20030053417A (ko) | 삼백초를 주성분으로 한 건강식품 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140319 |